BIIB
BIOGEN INC.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$215.50
−1.62%Next report
Analyst consensus
- Next report date
- Oct 28, 2026
- EPS estimate
- $2.07
- Revenue estimate
- $2.6B
Latest reported
- Last report date
- Jul 29, 2026
- EPS actual
- $3.60
- EPS estimate
- $2.99
- Revenue actual
- $2.7B
- Revenue estimate
- $2.5B
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 10
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +22.2%
- Revenue beats (12Q)
- 10
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $237
- PT range
- $175 – $300
- Analysts
- 17
11 Buy5 Hold1 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Jul 29, 2026 | $2.99 | $3.60 | Beat 20.36% | $2.7B |
| Apr 29, 2026 | $2.95 | $3.57 | Beat 21.02% | $2.5B |
| Feb 6, 2026 | $1.61 | $1.99 | Beat 23.60% | $2.3B |
| Oct 30, 2025 | $3.88 | $4.81 | Beat 23.97% | $2.5B |
| Jul 31, 2025 | $3.90 | $5.47 | Beat 40.26% | $2.6B |
| May 1, 2025 | $2.90 | $3.02 | Beat 4.14% | $2.4B |
| Feb 12, 2025 | $3.43 | $3.44 | Beat 0.29% | $2.5B |
| Oct 30, 2024 | $3.77 | $4.08 | Beat 8.22% | $2.5B |
| Aug 1, 2024 | $4.07 | $5.28 | Beat 29.73% | $2.4B |
| Feb 13, 2024 | $3.16 | $2.95 | Miss -6.65% | $2.4B |
| Nov 8, 2023 | $3.99 | $4.36 | Beat 9.27% | $2.5B |
| Jul 25, 2023 | $3.77 | $4.02 | Beat 6.63% | $2.5B |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 28, 2026